| 2024-04-19 | -0.57 % |
|
| 2024-04-18 | -0.29 % |
|
| 2024-04-15 | -0.39 % |
|
| 2024-04-12 | -1.09 % |
|
| 2024-04-11 | -0.18 % |
|
| 2024-04-08 | -0.11 % |
|
| 2024-04-03 | +0.41 % |
|
| 2024-04-02 | +0.11 % |
|
| 2024-03-27 | +0.39 % |
- The article provides information on Catalent, Inc. (CTLT) stock and analysts' ratings, with a consensus rating of "Hold" and a target price of $52.46. CTLT stock went up 0.39% last night, likely due to positive analyst recommendations and price target adjustments, such as an "equal weight" rating and raised price objectives by analysts like Barclays, UBS Group, Stephens, and Royal Bank of Canada.
- The article covers Catalent (CTLT) stock, which was up by 0.39% last night, as StockNews.com started coverage with a sell rating and various analysts provided ratings and price targets; the stock goes up due to the overall positive ratings and price targets from analysts, as well as the company's operations in developing and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.
|
| 2024-03-22 | -0.11 % |
|
| 2024-03-21 | -0.05 % |
|
| 2024-03-20 | -0.13 % |
- The article discusses Catalent, Inc. (CTLT) stock, which was down by -0.13% last night following Senior Vice President Scott Gunther's sale of 387 shares of CTLT stock at an average price of $56.20, leading to a total value of $21,749.40, with possible reasons for the decline being the negative earnings per share reported in the recent quarter and the subsequent decrease in revenue, as well as various analyst ratings and price targets.
- Summary: DNB Asset Management AS reduced its stake in Catalent, Inc. (NYSE:CTLT) by 75.9% in the 4th quarter, leading to a drop in CTLT stock, which was down by -0.13% last night. The company's earnings report for the quarter fell short of analyst estimates, impacting the stock.
Reason for CTLT Stock Going Down: The decrease in CTLT stock price can be attributed to DNB Asset Management AS significantly reducing its position in Catalent, Inc. during the fourth quarter, influencing the market perception and possibly leading to a decline in investor confidence. Additionally, the company's lower-than-expected quarterly earnings results further contributed to the decrease in the stock's value.
|
| 2024-03-19 | -0.02 % |
|
| 2024-03-18 | -0.46 % |
|
| 2024-03-15 | -0.85 % |
|
| 2024-03-12 | -0.55 % |
- Summary: Gotham Asset Management LLC recently acquired a stake in Catalent, Inc. (NYSE: CTLT) during the third quarter, which caused the stock to open down 0.55% on Tuesday. The stock decrease could potentially be related to the company's recent earnings report, where they reported lower-than-expected earnings and revenue for the quarter.
Reason for CTLT stock decline: The stock went down possibly due to the company's weak earnings report showing negative EPS and revenue below analyst expectations, leading to a negative return on equity and net margin, and a decrease in revenue on a year-over-year basis. This could have influenced investor sentiment and caused a decline in the stock price.
- The article discusses Halper Sadeh LLC investigating companies like Catalent, Inc. (NYSE: CTLT) for a potential sale to Novo Holdings at $63.50 per share, Everbridge, Inc. (NASDAQ: EVBG) for a sale to Thoma Bravo at $35.00 per share, and ZeroFox Holdings, Inc. (NASDAQ: ZFOX) for a sale to Haveli Investments at $1.14 per share, prompting the law firm to represent investors regarding these transactions due to potential violations of securities laws and fiduciary duties; Catalent (CTLT) stock declining by -0.55% may be a reaction to this investigation and potential sale.
- The article discusses Pomerantz LLP's investigation into Catalent, Inc. (CTLT) for possible securities fraud following the company's agreement to be sold to Novo Holdings, which led to a downgrade in stock due to reports of non-compliance with FDA standards at a Catalent manufacturing facility.
|
| 2024-03-11 | +0.53 % |
|
| 2024-03-08 | +0.27 % |
- Catalent (CTLT) stock was up by 0.27% last night, and the reason for this increase could be due to positive market speculation, news, or investor sentiment regarding the company's performance and outlook.
- The article discusses Novo Nordisk's upcoming experimental weight loss drugs, Amycretin and Cagrisema, and its optimistic outlook on their launch within this decade, potentially leading to an increase in Catalent (CTLT) stock due to its future collaborations with Novo Nordisk as a contract manufacturer.
- The article discusses Novo Nordisk's promising weight loss pill, Amycretin, that led to the company's stock surging, causing Novo Nordisk to become the 12th-most valuable company in the world, with CEO Lars Fruergaard Jørgensen mentioning that demand for weight loss drugs exceeds supply, explaining that Catalent's acquisition was made to address the shortage, which could possibly be a reason for the rise in Catalent (CTLT) stock.
|
| 2024-03-07 | -0.51 % |
- Catalent, Inc. published its fiscal 2023 Corporate Responsibility Report showcasing progress in environmental sustainability, diversity, and community support initiatives, with a commitment to reduce greenhouse gas emissions by 42% by 2030, which likely led to the stock going down due to investors potentially reacting to sustainability efforts impacting short-term financial performance.
- The article provides an overview of Catalent, Inc. (CTLT) stock performance, indicating that it was down by -0.51% on the previous night with an average rating of "Hold" from analysts, various price targets by different firms, and financial details, reporting a negative earnings per share for the last quarter. The stock declined possibly due to missing earnings estimates and a downgrade in recommendations by some analysts.
- Catalent (CTLT) stock was down by -0.51% last night, potentially due to uncertainties surrounding the closure of a deal with Novo Nordisk, with concerns raised about the need for additional capital expenditure if the deal falls through.
|
| 2024-03-05 | +0.02 % |
|
| 2024-03-04 | -0.42 % |
|
| 2024-03-01 | -0.26 % |
|
| 2024-02-29 | -1.04 % |
|
| 2024-02-28 | -0.45 % |
|
| 2024-02-27 | -0.15 % |
|
| 2024-02-23 | +0.63 % |
- The article discusses Korea Investment CORP's reduction in its position in Catalent, Inc. (NYSE:CTLT) by 35.4% during the third quarter, leading to an increase in the stock price last night. CTLT stock goes up as various institutional investors modify their holdings in the company, with firms like Thompson Siegel & Walmsley LLC and Canada Pension Plan Investment Board increasing their shares, which positively impacts the stock price.
- The article discusses Catalent (CTLT) stock, which saw a 0.63% increase in its value overnight following coverage initiation by StockNews.com with a sell rating and various analysts giving differing ratings ranging from sell to buy, with the stock opening at $58.40 and a market cap of $10.56 billion, attributing the rise to factors such as recent analyst ratings and possible institutional investments in the company.
- The article compares Passage Bio (PASG) and Humacyte (HUMA) based on various factors, such as volatility, profitability, valuation, and institutional ownership, with Passage Bio being considered more favorable by equities research analysts, resulting in its stock price going up.
|
| 2024-02-22 | +0.27 % |
|
| 2024-02-21 | +0.45 % |
|
| 2024-02-20 | -0.28 % |
|
| 2024-02-16 | +1.22 % |
|
| 2024-02-14 | +1.24 % |
|
| 2024-02-12 | +0.49 % |
|
| 2024-02-09 | +0.28 % |
|
| 2024-02-08 | +0.09 % |
|
| 2024-02-07 | -3.35 % |
|
| 2024-02-06 | -2.27 % |
|
| 2024-02-05 | +9.74 % |
|
| 2024-02-02 | +2.67 % |
|
| 2024-02-01 | +2.81 % |
|
| 2024-01-31 | -2.64 % |
|
| 2024-01-26 | +3.61 % |
|
| 2024-01-25 | +1.51 % |
|
| 2024-01-24 | +0.93 % |
|
| 2024-01-17 | -1.7 % |
|
| 2024-01-09 | +5.89 % |
|
| 2024-01-08 | +2.03 % |
|
| 2024-01-05 | +5.25 % |
|
| 2024-01-04 | +2.09 % |
|
| 2024-01-03 | -5.53 % |
|
| 2023-12-29 | -1.34 % |
|
| 2023-12-27 | +0.55 % |
|
| 2023-12-19 | +6.56 % |
|
| 2023-12-15 | +0.29 % |
|
| 2023-12-13 | +6.3 % |
|
| 2023-12-07 | -1.32 % |
|
| 2023-12-06 | -2.47 % |
|
| 2023-12-04 | -0.45 % |
|
| 2023-11-30 | -1.82 % |
|
| 2023-11-27 | -2.2 % |
|
| 2023-11-20 | +0.15 % |
|
| 2023-11-17 | +0.33 % |
|
| 2023-11-16 | +0.46 % |
|
| 2023-11-15 | +11.34 % |
|
| 2023-11-13 | -1.34 % |
|
| 2023-11-03 | +7.24 % |
|
| 2023-11-01 | -6.43 % |
|
| 2023-10-31 | -13.85 % |
|
| 2023-10-27 | +0.13 % |
- The article discusses the expectations for Novo Nordisk's third-quarter results and the potential impact on its stock price. Specifically, investors and analysts are looking for clarification on when supply constraints for Novo's weight-loss drug, Wegovy, in the United States will be lifted. The limited supply of Wegovy has led to soaring demand and has contributed to the significant increase in Novo's share price. The article suggests that the stock prices of Novo and its competitor, Eli Lilly, could be influenced by the resolution of these supply constraints.
- Catalent's stock (CTLT) went up by 0.13% following the increase in demand for obesity drugs, specifically Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, which has boosted the value and market share of these companies in the healthcare industry. The growing obesity crisis has led to a surge in demand for weight-loss drugs, leading analysts to predict the market could be worth $100 billion by 2030. As a result, companies involved in the manufacturing and assembly of self-injection pens, such as Catalent, Thermo Fisher, and PCI Pharma Services, are experiencing significant growth and investment in their capacity to meet the demand.
|
| 2023-10-24 | +0.62 % |
|
